Pfizer Oncology announces FDA approval of ELREXFIO™ (elranatamab-bcmm).
The following information is available for State Society review: § Full Prescribing Information Including Boxed Warning and Medication Guide
Read More...OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
The following information is available for State Society review: § Full Prescribing Information Including Boxed Warning and Medication Guide
Read More...AstraZeneca recently announced that new data from the ADAURA trial regarding AGRISSO® (osimertinib) has been released. The ADAURA trial is an ongoing study of TAGRISSO as adjuvant therapy after tumor resection in adult patients with completely resected Stage IB-IIIA EGFRm (exon 19 deletions or exon 21 L858R mutations) non-small cell lung cancer (NSCLC). TAGRISSO was approved as […]
Read More...AstraZeneca recently announced that the US Food and Drug Administration (FDA) has approved a new indication for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA. […]
Read More...Join the Oklahoma Society of Clinical Oncology, Inc. for our fall meeting on November 12, 2022, ASCO Direct™, an officially licensed program of the American Society of Clinical Oncology®. This meeting will break down the most clinically relevant abstracts from ASCO’s annual symposium, allowing attendees to engage with the latest strategies in oncology education. Details of the in-person meeting are:
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at kmussonokc@gmail.com or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.